Login to Your Account



Deal's Potential Could Exceed $1B

Concert Getting $35M Up Front in Early Stage GSK Agreement

By Jennifer Boggs


Wednesday, June 3, 2009
With the first Phase I data and the first patents relating to deuterium-modified compounds firmly in hand, Concert Pharmaceuticals Inc. set out looking for a partner and ended up scoring big by signing GlaxoSmithKline plc to a multiproduct collaboration that could be worth more than $1 billion in up-front and milestone payments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription